| Nov 21 |
4D Molecular initiated by Morgan Stanley at underweight
|
| Nov 14 |
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
|
| Nov 13 |
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 13 |
4D Molecular Therapeutics GAAP EPS of -$0.79 misses by $0.10
|
| Nov 13 |
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
|
| Oct 30 |
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
|
| Oct 14 |
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
|
| Oct 4 |
4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure
|
| Sep 25 |
4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
| Sep 23 |
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data
|
